JT

Reduced-Risk Products Science Update

Dr. Ian Jones, PhD JTI VP, Reduced-Risk Products Science

Forward-Looking Statements

This presentation contains forward-looking statements. These statements appear in a number of places in this document and include statements regarding the intent, belief, or current and future expectations of our management with respect to our business, financial condition and results of operations. In some cases, you can identify forward-looking statements by terms such as "may", "will", "should", "would", "expect", "intend", "project", "plan", "aim", "seek", "target", "anticipate", "believe", "estimate", "predict", "potential" or the negative of these terms or other similar terminology. These statements are not guarantees of future performance and are subject to various risks and uncertainties. Actual results, performance or achievements, or those of the industries in which we operate, may differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. In addition, these forward-looking statements are necessarily dependent upon assumptions, estimates and data that may be incorrect or imprecise and involve known and unknown risks and uncertainties. Forward-looking statements regarding operating results are particularly subject to a variety of assumptions, some or all of which may not be realized.

Risks, uncertainties or other factors that could cause actual results to differ materially from those expressed in any forward-looking statement include, without limitation:

- (1) increase in awareness of health concerns related to smoking;
- (2) regulatory developments; including, without limitation, tax increases and restrictions on sales, marketing, packaging, labeling and use of tobacco products, privately imposed restrictions and governmental investigations;
- (3) litigation around the world alleging adverse health and financial effects resulting from, or relating to, tobacco products;
- (4) our ability to further diversify our business beyond the traditional tobacco industry;
- (5) our ability to successfully expand internationally and make investments outside Japan;
- (6) competition and changing consumer preferences;
- (7) our ability to manage impacts derived from business diversification or business expansion;
- (8) economic, regulatory and political changes, such as nationalization, terrorism, wars and civil unrest, in countries in which we operate;
- (9) fluctuations in foreign exchange rates and the costs of raw materials; and
- (10) catastrophes, including natural disasters.

This presentation contains images of our products in some slides. Those slides have been included exclusively to illustrate JT Group's strategy or performance to our investors. They are not to be used for any other purpose.


© Copyright JT 2018

London – June 5, 2018

JT Investor Conference

Science is central to our RRP business

Multi-disciplinary expertise & international collaboration



Broadening spectrum of consumer needs



Focus on Reduced-Risk potential


Combining risk-reduction potential & product acceptance

To fulfill the Harm Reduction equation



The JT Group approach to assessment of RRP


The emission is our starting point





1 Emission | The risk cliff concept


Potential risk-reduction in T-Vapor products



ploom TFC

1 Emission | Dramatically reduced levels of TPM in Ploom TECH

Analysis of smoke & vapor constituents




Reference: Internal JT Group Studies. Note: "TPM" stands for Total Particulate Matter.




2 Uptake | Clinical study design

Biomarkers of exposure




PLOOM

2 Uptake | Reductions similar to smoking abstinence








3 Effect | Less biological impact compared to smoking




3 Effect | Less biological impact compared to smoking



© Copyright JT 2018 London – June 5, 2018 JT Investor Conference Reference: S. Munakata et al., 2017. Comparative effects of cigarette smoke and novel tobacco product vapor on in vitro cellular responses in human bronchial epithelial cells. Society of Toxicology 2017, Baltimore.


ploom

3 Effect | Observably less effect on tissue model, even at 10 times more puffs



4 Indoor Air Quality | Minimal impact

Exhaled breath analysis





ploom

4 Indoor Air Quality | Minimal impact

Cigarette Use Ploom TECH Use No Product Use [Units] 1,000.0 100.0 10.0 1.0 0.1 3-Ethenyl pyridine (ug/m3) Solanesol (ug/m3) Nicotine (ug/m3) Formaldehyde (ug/m3) Acetaldehyde (ug/m3) Acetone (ug/m3) Toluene (ug/m3) TVOC (ug/m3) PG (ug/m3) Glycerol (ug/m3) CO (ppm) Ammonia (ug/m3) SPM (mg/m3) © Copyright JT 2018 JT Investor Conference 17 London – June 5. 2018 Reference: H. Ichitsubo and M. Kotaki, 2018. Indoor air quality (IAQ) evaluation of a Novel Tobacco Vapor (NTV) product. Regul Toxicol Pharmacol. 92, 278-294.

Simulation of an occupied smoking lounge

Positive scientific results to date

Summary of Reduced-Risk potential



Our scientific assessments on Ploom TECH are providing very encouraging results, highlighting its strong Reduced-Risk potential

Committed to scientific communication

Follow our progress at JT-Science.com



© Copyright JT 2018

London – June 5, 2018

JT Investor Conference 19